mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-5-96-102mrj-1205Research ArticleОБЗОРЫREVIEWSНетоз в патогенезе антифосфолипидного синдрома и системной красной волчанкиNetosis in the pathogenesis of antiphospholipid syndrome and systemic lupus erythematosushttps://orcid.org/0000-0001-6685-7670НурбаеваК. С.NurbaevaK. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

Татьяна Магомедалиевна Решетняк

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

treshetnyak@yahoo.comhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522

2/1, Barrikadnaya Street, Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional EducationRussian Federation20211910202115596102Copyright © Нурбаева К.С., Решетняк Т.М., Лила А.М., 20212021Нурбаева К.С., Решетняк Т.М., Лила А.М.Nurbaeva K.S., Reshetnyak T.M., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1205

Антифосфолипидный синдром (АФС) и системная красная волчанка (СКВ) являются аутоиммунными заболеваниями. В последние годы АФС рассматривается как аутоиммунное тромбовоспалительное заболевание. Установлено, что клинические проявления АФС могут персистировать, прогрессировать со временем или дебютировать на фоне адекватной антикоагулянтной терапии и в некоторых случаях требуют назначения иммуносупрессивных препаратов, что указывает на роль аутоиммунного воспаления в их развитии. Образование внеклеточных нейтрофильных ловушек (neutrophil extracellular traps, NETs) является одним из связующих звеньев воспаления и тромбоза. Нетоз представляет собой процесс, при котором активированные нейтрофилы во внеклеточном пространстве формируют «сетеподобные» структуры (NETs). В данном обзоре рассмотрена роль нейтрофилов и нетоза в патогенезе АФС и СКВ.

Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are autoimmune diseases. In recent years, APS has been considered as an autoimmune thrombo-inflammatory disease. It has been established that clinical manifestations of APS can persist, progress over time, or debut during an adequate anticoagulant therapy and, in some cases, require administration of immunosuppressive drugs, which indicates the role of autoimmune inflammation in their development. The formation of extracellular neutrophil traps (neutrophil extracellular traps, NETs) is one of the connecting links of inflammation and thrombosis. Netosis is the process by which activated neutrophils in the extracellular space form netlike structures (NETs). This review examines the role of neutrophils and netosis in the pathogenesis of APS and SLE.

нетозвнеклеточные нейтрофильные ловушкитромбовоспалениеантифосфолипидный синдромсистемная красная волчанкаnetosisextracellular neutrophil trapsthrombus inflammationantiphospholipid syndromesystemic lupus erythematosusСтатья подготовлена в рамках научной темы «Разработка методов персонифицированной терапии ревматических заболеваний с коморбидной патологией» (АААА-А19-119021190151-3).The investigation has been conducted within scientific topic №АААА-А19-119021190151-3 «Development of methods for personalized therapy of rheumatic diseases with comorbid pathology».ReferencesРешетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71.Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (lecture). Nauchno-prakticheskaya revmatologiya. 2014;52(1):56-71. (In Russ.).Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.Насонов ЕЛ, редактор. Системная красная волчанка. В кн.: Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 113-41.Nasonov EL, editor. Systemic lupus erythematosus. In: Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTARMedia; 2017. P. 113-41.Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016 Jun;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085. Epub 2015 Dec 29.Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016 Jun;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085. Epub 2015 Dec 29.Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015 Apr 23;13:16. doi: 10.1186/s12959-015-0043-3. eCollection 2015.Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis. Thromb J. 2015 Apr 23;13:16. doi: 10.1186/s12959-015-0043-3. eCollection 2015.Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG.et.al. Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus. J Rheumatol. 2016 Mar;43(3):576-86. doi: 10.3899/jrheum.150506Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG.et.al. Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus. J Rheumatol. 2016 Mar;43(3):576-86. doi: 10.3899/jrheum.150506Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol. 2012;2012:428269. doi: 10.5402/2012/428269. Epub 2012 Jul 30.Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol. 2012;2012:428269. doi: 10.5402/2012/428269. Epub 2012 Jul 30.Cervera R, Serrano R, Pons-Estel GJ, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015 Jun; 74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838Cervera R, Serrano R, Pons-Estel GJ, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015 Jun; 74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838Wirestam L, Arve S, Linge P, Bengtsson AA. Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Front Immunol. 2019 Nov 22;10:2734. doi: 10.3389/fimmu.2019.02734. eCollection 2019.Wirestam L, Arve S, Linge P, Bengtsson AA. Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Front Immunol. 2019 Nov 22;10:2734. doi: 10.3389/fimmu.2019.02734. eCollection 2019.Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013 Jan;13(1):34-45. doi: 10.1038/nri3345. Epub 2012 Dec 7.Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013 Jan;13(1):34-45. doi: 10.1038/nri3345. Epub 2012 Dec 7.Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-67.Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immuno-inflammatory rheumatic diseases: at the intersection of thromboinflammation and autoimmunity problems. Nauchno-prakticheskaya revmatologiya. 2020;58(4):353-67. (In Russ.).Taraborelli M, Andreoli L, Tincani A. Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a «systemic disease». Best Pract Res Clin Rheumatol. 2012 Feb;26(1):79-90. doi: 10.1016/j.berh.2012.01.006.Taraborelli M, Andreoli L, Tincani A. Much more than thrombosis and pregnancy loss: The antiphospholipid syndrome as a «systemic disease». Best Pract Res Clin Rheumatol. 2012 Feb;26(1):79-90. doi: 10.1016/j.berh.2012.01.006.Yazici A. Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome. Eur J Rheumatol. 2020;7(4):180-3. doi:10.5152/eurjrheum.2020.20099Yazici A. Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome. Eur J Rheumatol. 2020;7(4):180-3. doi:10.5152/eurjrheum.2020.20099Xourgia E, Tektonidou MG. Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2020 Jul 22;22(9):51. doi: 10.1007/s11926-020-00935-2.Xourgia E, Tektonidou MG. Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2020 Jul 22;22(9):51. doi: 10.1007/s11926-020-00935-2.Решетняк ТМ, Чельдиева ФА, Нурбаева КС и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21. [Reshetnyak TM, Chel'dieva FA, Nurbaeva KS, et al. Antiphospholipid syndrome: diagnosis, mechanism of development, therapy issues. Tromboz, gemostaz i reologiya. 2020;(4):4-21. (In Russ.)].Решетняк ТМ, Чельдиева ФА, Нурбаева КС и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21. [Reshetnyak TM, Chel'dieva FA, Nurbaeva KS, et al. Antiphospholipid syndrome: diagnosis, mechanism of development, therapy issues. Tromboz, gemostaz i reologiya. 2020;(4):4-21. (In Russ.)].Андрюков БГ, Богданова ВД, Ляпун ИН. Фенотипическая гетерогенность нейтрофилов: новые антимикробные характеристики и диагностические технологии. Гематология и трансфузиология. 2019; 64(2):211-21.Andryukov BG, Bogdanova VD, Lyapun IN. Phenotypic heterogeneity of neutrophils: new antimicrobial characteristics and diagnostic technologies. Gematologiya i transfuziologiya. 2019;64(2):211-21. (In Russ.).Hassani M, Hellebrekers P, Chen N, et al. On the origin of low-density neutrophils. J Leukoc Biol. 2020 May;107(5):809-18. doi: 10.1002/JLB.5HR0120-459R. Epub 2020 Mar 14.Hassani M, Hellebrekers P, Chen N, et al. On the origin of low-density neutrophils. J Leukoc Biol. 2020 May;107(5):809-18. doi: 10.1002/JLB.5HR0120-459R. Epub 2020 Mar 14.Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004 Mar 5;303(5663):1532-5. doi: 10.1126/science.1092385.Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004 Mar 5;303(5663):1532-5. doi: 10.1126/science.1092385.Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol. 2012 Sep 15;189(6): 2689-95. doi: 10.4049/jimmunol.1201719.Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol. 2012 Sep 15;189(6): 2689-95. doi: 10.4049/jimmunol.1201719.Воробьева НВ. Нейтрофильные внеклеточные ловушки: новые аспекты. Вестник Московского университета. Серия 16. Биология. 2020;75(4):210-25.Vorob'eva NV. Neutrophil extracellular traps: new aspects. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2020;75(4):210-25. (In Russ.).Li Y, Wang W, Yang F, et al. The regulatory roles of neutrophils in adaptive immunity. Cell Commun Signal. 2019 Nov 14;17(1):147. doi: 10.1186/s12964-019-0471-y.Li Y, Wang W, Yang F, et al. The regulatory roles of neutrophils in adaptive immunity. Cell Commun Signal. 2019 Nov 14;17(1):147. doi: 10.1186/s12964-019-0471-y.Minns D, Smith KJ, Findlay EG. Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents. Mediators Inflamm. 2019 Mar 10;2019:8968943. doi: 10.1155/2019/8968943. eCollection 2019.Minns D, Smith KJ, Findlay EG. Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents. Mediators Inflamm. 2019 Mar 10;2019:8968943. doi: 10.1155/2019/8968943. eCollection 2019.Klopf J, Brostjan C, Eilenberg W, et al. Neutrophil Extracellular Traps and Their Implications in Cardiovascular and Inflammatory Disease. Int J Mol Sci. 2021 Jan 8;22(2):559. doi: 10.3390/ijms22020559.Klopf J, Brostjan C, Eilenberg W, et al. Neutrophil Extracellular Traps and Their Implications in Cardiovascular and Inflammatory Disease. Int J Mol Sci. 2021 Jan 8;22(2):559. doi: 10.3390/ijms22020559.Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):448-53. doi: 10.1097/BOR.0000000000000197.Smith CK, Kaplan MJ. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2015 Sep;27(5):448-53. doi: 10.1097/BOR.0000000000000197.Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011 Sep 27;7(12):691-9. doi: 10.1038/nrrheum.2011.132.Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011 Sep 27;7(12):691-9. doi: 10.1038/nrrheum.2011.132.Tay SH, Celhar T, Fairhurst AM. Low-Density Neutrophils in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Oct;72(10):1587-95. doi: 10.1002/art.41395.Epub 2020 Aug 26.Tay SH, Celhar T, Fairhurst AM. Low-Density Neutrophils in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Oct;72(10):1587-95. doi: 10.1002/art.41395.Epub 2020 Aug 26.Rahman S, Sagar D, Hanna RN, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019 Jul;78(7):957-66. doi: 10.1136/annrheumdis-2018-214620. Epub 2019 Apr 30.Rahman S, Sagar D, Hanna RN, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019 Jul;78(7):957-66. doi: 10.1136/annrheumdis-2018-214620. Epub 2019 Apr 30.Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9;3(73):73ra20. doi: 10.1126/scitranslmed. 3001201.Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9;3(73):73ra20. doi: 10.1126/scitranslmed. 3001201.Van den Hoogen LL, van der Linden M, Meyaard L, et al. Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome. Ann Rheum Dis. 2020 Oct; 79(10):e135. doi: 10.1136/annrheumdis-2019-215781. Epub 2019 Jun 8.Van den Hoogen LL, van der Linden M, Meyaard L, et al. Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome. Ann Rheum Dis. 2020 Oct; 79(10):e135. doi: 10.1136/annrheumdis-2019-215781. Epub 2019 Jun 8.De Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol. 2019 Jan;16(1):19-27. doi: 10.1038/s41423-018-0024-0. Epub 2018 Mar 23.De Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol. 2019 Jan;16(1):19-27. doi: 10.1038/s41423-018-0024-0. Epub 2018 Mar 23.Hakkim A, Fü rnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8. doi: 10.1073/pnas.0909927107. Epub 2010 May 3.Hakkim A, Fü rnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8. doi: 10.1073/pnas.0909927107. Epub 2010 May 3.Leffler J, Gullstrand B, Jö nsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013 Aug 14;15(4):R84. doi: 10.1186/ar4264.Leffler J, Gullstrand B, Jö nsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther. 2013 Aug 14;15(4):R84. doi: 10.1186/ar4264.Salemme R, Peralta LN, Meka SH, et al. The Role of NETosis in Systemic Lupus Erythematosus. J Cell Immunol. 2019;1(2): 33-42. doi: 10.33696/immunology.1.008.Epub 2019 Nov 12.Salemme R, Peralta LN, Meka SH, et al. The Role of NETosis in Systemic Lupus Erythematosus. J Cell Immunol. 2019;1(2): 33-42. doi: 10.33696/immunology.1.008.Epub 2019 Nov 12.Lerner RG, Goldstein R, Cummings G, et al. Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med. 1971 Oct;138(1):145-8. doi: 10.3181/00379727-138-35848Lerner RG, Goldstein R, Cummings G, et al. Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med. 1971 Oct;138(1):145-8. doi: 10.3181/00379727-138-35848Hirahashi J, Hishikawa K, Kaname S, et al. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation. 2009 Sep 29;120(13):1255-65. doi: 10.1161/CIRCULATIONAHA.109. 873695. Epub 2009 Sep 14.Hirahashi J, Hishikawa K, Kaname S, et al. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation. 2009 Sep 29;120(13):1255-65. doi: 10.1161/CIRCULATIONAHA.109. 873695. Epub 2009 Sep 14.Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880-5. doi:10.1073/pnas.1005743107Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880-5. doi:10.1073/pnas.1005743107Von Brü hl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012 Apr 9;209(4):819-35. doi: 10.1084/jem.20112322. Epub 2012 Mar 26.Von Brü hl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012 Apr 9;209(4):819-35. doi: 10.1084/jem.20112322. Epub 2012 Mar 26.Kambas K, Mitroulis I, Ritis K. The emerging role of neutrophils in thrombosis-the journey of TF through NETs. Front Immunol. 2012 Dec 18;3:385. doi: 10.3389/fimmu.2012.00385. eCollection 2012.Kambas K, Mitroulis I, Ritis K. The emerging role of neutrophils in thrombosis-the journey of TF through NETs. Front Immunol. 2012 Dec 18;3:385. doi: 10.3389/fimmu.2012.00385. eCollection 2012.Barranco-Medina S, Pozzi N, Vogt AD, et al. Histone H4 promotes prothrombin autoactivation. J Biol Chem. 2013 Dec 13; 288(50):35749-57. doi: 10.1074/jbc.M113.509786. Epub 2013 Oct 30.Barranco-Medina S, Pozzi N, Vogt AD, et al. Histone H4 promotes prothrombin autoactivation. J Biol Chem. 2013 Dec 13; 288(50):35749-57. doi: 10.1074/jbc.M113.509786. Epub 2013 Oct 30.VarjЬ I, Longstaff C, Szabo L, et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost. 2015 Jun; 113(6):1289-98. doi: 10.1160/TH14-08-0669VarjЬ I, Longstaff C, Szabo L, et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost. 2015 Jun; 113(6):1289-98. doi: 10.1160/TH14-08-0669Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010 Aug;16(8):887-96. doi: 10.1038/nm.2184. Epub 2010 Aug 1.Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010 Aug;16(8):887-96. doi: 10.1038/nm.2184. Epub 2010 Aug 1.Zuo Y, Kanthi Y, Knight JS, et al. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol. 2021 Mar;35(1): 101661. doi: 10.1016/j.berh.2021.101661. Epub 2021 Jan 13.Zuo Y, Kanthi Y, Knight JS, et al. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol. 2021 Mar;35(1): 101661. doi: 10.1016/j.berh.2021.101661. Epub 2021 Jan 13.Yuen J, Pluthero FG, Douda DN, et al. Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front Immunol. 2016 Apr 14;7:137. doi: 10.3389/fimmu.2016.00137. eCollection 2016.Yuen J, Pluthero FG, Douda DN, et al. Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front Immunol. 2016 Apr 14;7:137. doi: 10.3389/fimmu.2016.00137. eCollection 2016.Thalin C, Hisada Y, Lundströ m S, et al. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer- Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1724-38. doi: 10.1161/ATVBAHA.119.312463.Epub 2019 Jul 18.Thalin C, Hisada Y, Lundströ m S, et al. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer- Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1724-38. doi: 10.1161/ATVBAHA.119.312463.Epub 2019 Jul 18.Laridan E, Martinod K, De Meyer SF. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi: 10.1055/s-0038-1677040Laridan E, Martinod K, De Meyer SF. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi: 10.1055/s-0038-1677040Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factorenriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 Nov 2;130(11):6151-7.doi: 10.1172/JCI141374Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factorenriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 Nov 2;130(11):6151-7.doi: 10.1172/JCI141374Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.Arthritis Rheumatol. 2015 Nov;67(11): 2990-3003. doi: 10.1002/art.39247.Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.Arthritis Rheumatol. 2015 Nov;67(11): 2990-3003. doi: 10.1002/art.39247.Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis Rheumatol. 2017 Mar;69(3):655-67. doi: 10.1002/art.39938Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis Rheumatol. 2017 Mar;69(3):655-67. doi: 10.1002/art.39938Zha C, Zhang W, Gao F, et al. Anti-β2GPI/β2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology. 2018 Aug;138:140-50. doi: 10.1016/j.neuropharm.2018.06.001Zha C, Zhang W, Gao F, et al. Anti-β2GPI/β2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology. 2018 Aug;138:140-50. doi: 10.1016/j.neuropharm.2018.06.001You Y, Liu Y, Li F, et al. Anti-β2GPI/ β2GPI induces human neutrophils to generate NETs by relying on ROS. Cell Biochem Funct. 2019 Mar;37(2):56-61. doi: 10.1002/cbf.3363.Epub 2019 Jan 30.You Y, Liu Y, Li F, et al. Anti-β2GPI/ β2GPI induces human neutrophils to generate NETs by relying on ROS. Cell Biochem Funct. 2019 Mar;37(2):56-61. doi: 10.1002/cbf.3363.Epub 2019 Jan 30.Lu Y, Dong Y, Zhang Y, et al. Antiphospholipid antibody-activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome. J Cell Mol Med. 2020 Jun;24(12): 6690-703. doi: 10.1111/jcmm.15321Lu Y, Dong Y, Zhang Y, et al. Antiphospholipid antibody-activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome. J Cell Mol Med. 2020 Jun;24(12): 6690-703. doi: 10.1111/jcmm.15321Van der Linden M, van den Hoogen LL, Westerlaken GHA, et al. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology (Oxford). 2018 Jul 1;57(7): 1228-34. doi: 10.1093/rheumatology/key067Van der Linden M, van den Hoogen LL, Westerlaken GHA, et al. Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology (Oxford). 2018 Jul 1;57(7): 1228-34. doi: 10.1093/rheumatology/key067Leffler J, Stojanovich L, Shoenfeld Y, et al. Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clin Exp Rheumatol. Jan-Feb 2014;32(1):66-70. Epub 2013 Dec 2.Leffler J, Stojanovich L, Shoenfeld Y, et al. Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clin Exp Rheumatol. Jan-Feb 2014;32(1):66-70. Epub 2013 Dec 2.Zuo Y, Yalavarthi S, Gockman K, et al. Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. Arthritis Rheumatol. 2020 Dec;72(12):2130-5. doi: 10.1002/art.41460Zuo Y, Yalavarthi S, Gockman K, et al. Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. Arthritis Rheumatol. 2020 Dec;72(12):2130-5. doi: 10.1002/art.41460Van den Hoogen LL, Fritsch-Stork RD, van Roon JA, Radstake TR. Low-Density Granulocytes Are Increased in Antiphospholipid Syndrome and Are Associated With Anti-β2 -Glycoprotein I Antibodies: Comment on the Article by Yalavarthi et al. Arthritis Rheumatol. 2016 May;68(5):1320-1. doi: 10.1002/art.39576Van den Hoogen LL, Fritsch-Stork RD, van Roon JA, Radstake TR. Low-Density Granulocytes Are Increased in Antiphospholipid Syndrome and Are Associated With Anti-β2 -Glycoprotein I Antibodies: Comment on the Article by Yalavarthi et al. Arthritis Rheumatol. 2016 May;68(5):1320-1. doi: 10.1002/art.39576Mauracher LM, Krall M, Roiβ J, et al. Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. Rheumatology (Oxford). 2021 Apr 6;60(4): 1687-99. doi: 10.1093/rheumatology/keaa532Mauracher LM, Krall M, Roiβ J, et al. Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. Rheumatology (Oxford). 2021 Apr 6;60(4): 1687-99. doi: 10.1093/rheumatology/keaa532Sule G, Kelley WJ, Gockman K, et al. Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac-1. Arthritis Rheumatol. 2020 Jan;72(1):114-124.doi: 10.1002/art.41057.Sule G, Kelley WJ, Gockman K, et al. Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac-1. Arthritis Rheumatol. 2020 Jan;72(1):114-124.doi: 10.1002/art.41057.Knight JS, Meng H, Coit P, et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight. 2017 Sep 21;2(18): e93897. doi: 10.1172/jci.insight.93897.Knight JS, Meng H, Coit P, et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight. 2017 Sep 21;2(18): e93897. doi: 10.1172/jci.insight.93897.

The authors declare that there are no conflicts of interest present.